CASI Pharmaceuticals Inc
NASDAQ:CASI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CASI Pharmaceuticals Inc
Total Other Income
CASI Pharmaceuticals Inc
Total Other Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Other Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CASI Pharmaceuticals Inc
NASDAQ:CASI
|
Total Other Income
$40k
|
CAGR 3-Years
-58%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Other Income
-$5.8B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-84%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Other Income
-$2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Other Income
$628m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Other Income
$3.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Other Income
$33.7m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
18%
|
|
CASI Pharmaceuticals Inc
Glance View
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company is headquartered in Rockville, Maryland and currently employs 168 full-time employees. The firm is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States and throughout the world. The company is also focused on acquiring, developing, and commercializing products that augment its hematology-oncology therapeutic focus as well as other areas of unmet medical need. The Company’s operations in China are conducted primarily through its subsidiaries, which include CASI Pharmaceuticals (China) Co., Ltd. (CASI China), which is wholly owned and is located in Beijing, China, and CASI Pharmaceuticals (Wuxi) Co., Ltd. (CASI Wuxi), which is located in Wuxi, China. Its commercial product, EVOMELA, is developed for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The Company’s other core hematology/oncology assets in its pipeline include CNCT19, BI-1206, CB-5339 and CID-103.
See Also
What is CASI Pharmaceuticals Inc's Total Other Income?
Total Other Income
40k
USD
Based on the financial report for Jun 30, 2025, CASI Pharmaceuticals Inc's Total Other Income amounts to 40k USD.
What is CASI Pharmaceuticals Inc's Total Other Income growth rate?
Total Other Income CAGR 5Y
5%
The average annual Total Other Income growth rates for CASI Pharmaceuticals Inc have been -58% over the past three years , 5% over the past five years .
